Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.49 USD | +3.85% | +8.66% | -36.88% |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Sales forecast by analysts have been recently revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-36.88% | 2.09B | C+ | ||
-4.72% | 182B | C+ | ||
+3.96% | 112B | C | ||
-2.93% | 68.58B | A | ||
+6.30% | 51.58B | B- | ||
+8.02% | 44.24B | B- | ||
+7.89% | 43.65B | B+ | ||
+26.18% | 32.46B | B | ||
+17.33% | 25.99B | A- | ||
+0.57% | 25.61B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IART Stock
- Ratings Integra LifeSciences Holdings Corporation